Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium that is a normal inhabitant of the human intestine. It is a member of the Enterococcus genus, which includes several species of bacteria that are commonly found in the environment and in the human body. Enterococcus faecalis is known to cause a wide range of infections, including urinary tract infections, endocarditis, and bacteremia. Despite its clinical significance, there is still much to be learned about this microbe. This article will explore the current understanding of Enterococcus faecalis, including its structure, physiology, genetics, and virulence factors.
Enterococcus faecalis is a small, Gram-positive, spherical bacterium. It is approximately 1.5-2 µm in diameter and is non-motile. The cell wall of Enterococcus faecalis is composed of a thick peptidoglycan layer, which is surrounded by a thin layer of lipoteichoic acid. The cell wall is responsible for the bacterium’s resistance to a variety of antibiotics, including penicillin and vancomycin.
Enterococcus faecalis is a facultative anaerobe, which means it can grow in both aerobic and anaerobic environments. It is able to utilize a variety of carbon sources, including glucose, fructose, sucrose, and glycerol. It is also capable of utilizing a variety of nitrogen sources, including ammonia, nitrate, and nitrite. Enterococcus faecalis is able to survive in a wide range of temperatures, pH levels, and salt concentrations.
Enterococcus faecalis is a genetically diverse species, which can be divided into several distinct clades. These clades are differentiated by their genetic makeup, which can be used to determine the virulence potential of a particular strain. Enterococcus faecalis is capable of producing a variety of virulence factors, including enterococcal surface protein (Esp), cytolysin, and gelatinase. These virulence factors are responsible for the bacterium’s ability to cause a wide range of infections.
Enterococcus faecalis is a major cause of nosocomial infections, which are infections acquired in a healthcare setting. The most common infections caused by Enterococcus faecalis are urinary tract infections, bacteremia, and endocarditis. These infections are often difficult to treat due to the bacterium’s resistance to many antibiotics. Enterococcus faecalis is also known to cause opportunistic infections in immunocompromised individuals.
Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium that is a normal inhabitant of the human intestine. It is a major cause of nosocomial infections, including urinary tract infections, bacteremia, and endocarditis. Despite its clinical significance, there is still much to be learned about this microbe. This article has explored the current understanding of Enterococcus faecalis, including its structure, physiology, genetics, and virulence factors.
1.
Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes
2.
A computer-aided diagnostic system for improved detection of breast cancer.
3.
Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.
4.
Metastatic Cancer 'Thrivers'; Celebrity Cancer Diagnoses; 'Would He Have Lived?'
5.
According to JAMA, statin use may increase cancer-related survival in breast cancer patients.
1.
The New Era of Oncology: Key Updates and Clinical Insights
2.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
3.
Anesthetic Techniques and Strategies in Cancer Surgery: Unveiling the Impact on Oncological Outcomes
4.
Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment
5.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
4.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation